

Refine Search

Search Results -

Terms	Documents
L6 and oral	14

Database:

- US Pre-Grant Publication Full-Text Database
- US Patents Full-Text Database
- US OCR Full-Text Database
- EPO Abstracts Database
- JPO Abstracts Database
- Derwent World Patents Index
- IBM Technical Disclosure Bulletins

Search:

L7

Refine Search

Recall Text

Clear

Interrupt

Search History

DATE: Wednesday, May 10, 2006 [Printable Copy](#) [Create Case](#)

<u>Set Name</u> side by side	<u>Query</u>	<u>Hit Count</u>	<u>Set Name</u> result set
<i>DB=PGPB,USPT,USOC,EPAB,JPAB,DWPI,TDBD; PLUR=YES; OP=OR</i>			
<u>L7</u>	L6 and oral	14	<u>L7</u>
<u>L6</u>	L5 and particle	14	<u>L6</u>
<u>L5</u>	L4 and @pd<20031124	14	<u>L5</u>
<u>L4</u>	L3 and diameter	45	<u>L4</u>
<u>L3</u>	L2 and tablet	70	<u>L3</u>
<u>L2</u>	L1 and (dissol\$ near5 rate)	73	<u>L2</u>
<u>L1</u>	modafinil	371	<u>L1</u>

END OF SEARCH HISTORY

(FILE 'HOME' ENTERED AT 21:16:33 ON 10 MAY 2006)

FILE 'REGISTRY' ENTERED AT 21:16:41 ON 10 MAY 2006

E "MODAFINIL"/CN 25

L1 1 S E3

FILE 'CAPLUS, MEDLINE' ENTERED AT 21:17:47 ON 10 MAY 2006

L2 811 S MODAFINIL OR (68693-11-8/RN)

L3 49 S L2 AND (PROVIGIL OR MODAPHONIL OR MODIODAL OR (BENZHYDRYLSULF

L4 0 S L3 AND TABLET (8A) ORAL

L5 0 S L3 AND (TABLET(8A) ORAL)

L6 0 S L3 AND TABLET

L7 11 S L3 AND ORAL

L8 7 DUPLICATE REMOVE L7 (4 DUPLICATES REMOVED)

FILE 'STNGUIDE' ENTERED AT 21:21:39 ON 10 MAY 2006

L9 ANSWER 2 OF 38 MEDLINE on STN

TI A systematic review of **modafinil**: potential clinical uses and mechanisms of action.

AB BACKGROUND: **Modafinil** is a novel wake-promoting agent that has U.S. Food and Drug Administration approval for narcolepsy and shift work sleep disorder and as adjunctive treatment of obstructive sleep apnea/hypopnea syndrome. **Modafinil** has a novel mechanism and is theorized to work in a localized manner, utilizing hypocretin, histamine, epinephrine, gamma-aminobutyric acid, and glutamate. It is a well-tolerated medication with low propensity for abuse and is frequently used for off-label indications. The objective of this study was to systematically review the available evidence supporting the clinical use of **modafinil**. DATA SOURCES: The search term **modafinil** OR **Provigil** was searched on PubMed. Selected articles were mined for further potential sources of data. Abstracts from major scientific conferences were reviewed. Lastly, the manufacturer of **modafinil** in the United States was asked to provide all publications, abstracts, and unpublished data regarding studies of **modafinil**. DATA SYNTHESIS: There have been 33 double-blind, placebo-controlled trials of **modafinil**. Additionally, numerous smaller studies have been performed, and case reports of **modafinil**'s use abound in the literature. CONCLUSIONS: **Modafinil** is a promising drug with a large potential for many uses in psychiatry and general medicine. Treating daytime sleepiness is complex, and determining the precise nature of the sleep disorder is vital. **Modafinil** may be an effective agent in many sleep conditions. To date, the strongest evidence among off-label uses exists for the use of **modafinil** in attention-deficit disorder, postanesthetic sedation, and cocaine dependence and withdrawal and as an adjunct to antidepressants for depression.

ACCESSION NUMBER: 2006246551 IN-PROCESS

DOCUMENT NUMBER: PubMed ID: 16669720

TITLE: A systematic review of **modafinil**: potential clinical uses and mechanisms of action.

AUTHOR: Ballon Jacob S; Feifel David

CORPORATE SOURCE: From the Department of Psychiatry, University of California, San Diego, San Diego (Drs. Ballon and Feifel); and the Department of Psychiatry and Behavioral Science, Stanford University, Stanford, Calif. (Dr. Ballon).

SOURCE: The Journal of clinical psychiatry, (2006 Apr) Vol. 67, No. 4, pp. 554-66.

Journal code: 7801243. ISSN: 0160-6689.

PUB. COUNTRY: United States

DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)

LANGUAGE: English

FILE SEGMENT: NONMEDLINE; IN-DATA-REVIEW; IN-PROCESS; NONINDEXED; Priority Journals

ENTRY DATE: Entered STN: 4 May 2006

Last Updated on STN: 4 May 2006

L9 ANSWER 3 OF 38 MEDLINE on STN

TI A review of the use of **modafinil** for attention-deficit hyperactivity disorder.

AB **Modafinil** (**Provigil**) is a novel wakefulness-promoting agent that has been shown to have greater efficacy than placebo in the treatment of attention-deficit hyperactivity disorder (ADHD) in children and adults. In particular, three large, drug-company sponsored trials of a film-coated formulation of **modafinil** (**modafinil**-ADHD; Sparlon) in children and adolescents with ADHD demonstrated consistent improvements in ADHD symptoms compared with placebo. Mean reductions in symptom ratings (measured using the ADHD-Rating Scale-IV school version questionnaire) ranged from 15.0 to 19.7 (7.3 to 10.1 for placebo). The most common adverse events were insomnia, headache and

decreased appetite. **Modafinil** was generally well tolerated with most side effects considered mild to moderate in severity. **Modafinil** may have advantages over current therapies for ADHD in that it can be administered once daily and has fewer reinforcing properties than traditional stimulants. **Modafinil** could potentially be a valuable new treatment option for patients with ADHD. However, rigorous comparative studies with current first-line treatments for ADHD and longer-term independent studies are necessary before **modafinil's** role in the treatment of ADHD can be fully established.

ACCESSION NUMBER: 2006229778 IN-PROCESS
DOCUMENT NUMBER: PubMed ID: 16623645
TITLE: A review of the use of **modafinil** for attention-deficit hyperactivity disorder.
AUTHOR: Turner Danielle
CORPORATE SOURCE: University of Cambridge, Department of Psychiatry, Box 189, Addenbrooke's Hospital, Cambridge, CB2 2QQ UK..
dct23@cam.ac.uk
SOURCE: Expert review of neurotherapeutics, (2006 Apr) Vol. 6, No. 4, pp. 455-68.
Journal code: 101129944. E-ISSN: 1744-8360.
PUB. COUNTRY: England: United Kingdom
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)
LANGUAGE: English
FILE SEGMENT: NONMEDLINE; IN-PROCESS; NONINDEXED; Priority Journals
ENTRY DATE: Entered STN: 27 Apr 2006
Last Updated on STN: 27 Apr 2006

L9 ANSWER 4 OF 38 CAPLUS COPYRIGHT 2006 ACS on STN

TI **Modafinil** compositions

AB A pharmaceutical composition comprising **modafinil** in the form of particles, wherein greater than 5% to about 50% of the cumulative total of the **modafinil** particles in the composition have a particle size greater than about 200 μ as determined by a U.S. Sieve Number 75. The present inventors have unexpectedly determined that the pharmaceutical compns. of the invention exhibit comparable stability, dissoln., and bioavailability as compared to **Provigil** which is a com.-available **modafinil** formulation.

ACCESSION NUMBER: 2005:547285 CAPLUS
DOCUMENT NUMBER: 143:65492
TITLE: **Modafinil** compositions
INVENTOR(S): Patel, Ashish Anilbhai; Barbera, Gary
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 7 pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2005137264	A1	20050623	US 2003-743366	20031222
PRIORITY APPLN. INFO.:			US 2003-743366	20031222

L9 ANSWER 21 OF 38 MEDLINE on STN

TI By the way, doctor. What can you tell me about the new drug **Provigil**? I've read that it helps people stay awake without feeling jittery. For those of us who work a lot of overtime, it sounds like a dream come true.

ACCESSION NUMBER: 2003064778 MEDLINE
DOCUMENT NUMBER: PubMed ID: 12543593
TITLE: By the way, doctor. What can you tell me about the new drug **Provigil**? I've read that it helps people stay awake

without feeling jittery. For those of us who work a lot of overtime, it sounds like a dream come true.

AUTHOR: Robb-Nicholson Celeste
SOURCE: Harvard women's health watch, (2003 Jan) Vol. 10, No. 5, pp. 8.
Journal code: 9423147. ISSN: 1070-910X.


PUB. COUNTRY: United States
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)
LANGUAGE: English
FILE SEGMENT: Consumer Health
ENTRY MONTH: 200303
ENTRY DATE: Entered STN: 11 Feb 2003
Last Updated on STN: 7 Mar 2003
Entered Medline: 6 Mar 2003

L9 ANSWER 36 OF 38 CAPLUS COPYRIGHT 2006 ACS on STN
TI **Modafinil: Modiodal**
AB A review, with no refs. The pharmacodynamics, pharmacokinetics, and dosage of **modafinil** are discussed for treatment of narcolepsy or idiopathic hypersomnia.

ACCESSION NUMBER: 1997:182190 CAPLUS
DOCUMENT NUMBER: 126:258244
TITLE: **Modafinil: Modiodal**
AUTHOR(S): Rochegude, S.; Constant, H.
CORPORATE SOURCE: Pharmacie, Hopital Debrousse, Lyon, 69322, Fr.
SOURCE: Lyon Pharmaceutique (1996), 47(7), 363-366
CODEN: LYPHAD; ISSN: 0024-7804

PUBLISHER: Elsevier
DOCUMENT TYPE: Journal; General Review
LANGUAGE: French

L1 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2006 ACS on STN
 RN 68693-11-8 REGISTRY
 CN Acetamide, 2-[(diphenylmethyl)sulfinyl]- (9CI) (CA INDEX NAME)
 OTHER NAMES:
 CN (±)-Modafinil
 CN 2-(Benzhydrylsulfinyl)acetamide
 CN CEP 1538
 CN CRC 40476
 CN CRL 40476
 CN DEP 1538
 CN **Modafinil**
 CN Modaphonil
 CN Modiodal
 CN Provigil
 FS 3D CONCORD
 DR 112111-49-6
 MF C15 H15 N O2 S
 CI COM
 LC STN Files: ADISINSIGHT, ADISNEWS, AGRICOLA, ANABSTR, BEILSTEIN*, BIOSIS,
 BIOTECHNO, CA, CAPLUS, CASREACT, CBNB, CHEMCATS, CHEMLIST, CIN, DDFU,
 DRUGU, EMBASE, IMSCOSEARCH, IMSDRUGNEWS, IMSPATENTS, IMSRESEARCH, IPA,
 MEDLINE, MRCK*, PATDPASPC, PHAR, PROMT, PROUSDDR, PS, RTECS*, SYNTHLINE,
 TOXCENTER, USAN, USPAT2, USPATFULL
 (*File contains numerically searchable property data)
 Other Sources: WHO
 DT.CA CAPLUS document type: Dissertation; Journal; Patent
 RL.P Roles from patents: BIOL (Biological study); MSC (Miscellaneous); PREP
 (Preparation); PROC (Process); PRP (Properties); RACT (Reactant or
 reagent); USES (Uses)
 RLD.P Roles for non-specific derivatives from patents: BIOL (Biological
 study); PROC (Process); USES (Uses)
 RL.NP Roles from non-patents: ANST (Analytical study); BIOL (Biological
 study); PREP (Preparation); PROC (Process); PRP (Properties); USES
 (Uses)
 RLD.NP Roles for non-specific derivatives from non-patents: BIOL (Biological
 study); PREP (Preparation)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

346 REFERENCES IN FILE CA (1907 TO DATE)
 4 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
 347 REFERENCES IN FILE CAPLUS (1907 TO DATE)